10 research outputs found
P1-062: Comparison of WHO and RECIST criteria for assessment of response in patients with lung cancer- A pilot study
Case Report - Unusual metastasis in colorectal cancer
Metastasis from colorectal carcinoma occurs by either lymphatic or
hematogenous spread. The most common sites of colorectal metastasis are
the liver and lung. Involvement of the skin, muscles and bones are
quite rare. The prognosis in such patients is usually poor. Herewith,
we are reporting a case of colonic carcinoma who had cutaneous
metastasis, muscular involvement and diffuse skeletal metastasis. At
the end, she had brain metastasis, but liver and lung involvement was
not observed till the end
P1-062: Comparison of WHO and RECIST criteria for assessment of response in patients with lung cancer- A pilot study
Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors
Background: In patients with small-volume disseminated disease of germ
cell tumors, cure can be achieved with four cycles of bleomycin,
etoposide, and cisplatin (BEP). However, around 20% of these cases are
not curable. Strategies to improve cure rates have shown that none of
the currently available modalities were superior to the others. Among
the most used ones, BEP and VIP (etoposide, cisplatin, and ifosfamide)
have been the most studied. However, there are no reports comparing the
two, except for a few in abstract forms from southern India. Therefore,
we did a treatment outcome and cost-effectiveness analysis of two
chemotherapeutic regimens (BEP vs VIP) that are used in poor-prognosis
metastatic germ cell tumors. Materials and Methods: All male patients
with germ cell tumors, diagnosed as having poor risk by IGCCCG, between
January 2002 and December 2004 were included in the study. Clinical,
laboratory, and other data were recorded. The patients were stratified
into two categories on the basis of the type of chemotherapeutic
regimen they received. Results: In all, 46 patients were analyzed, with
a median follow up of 26.6 months. The baseline characteristics (age,
stage, PS, histology, and serum markers) were not different in the two
treatment arms. There is no significant difference in the outcome with
either of the chemotherapeutic modalities. VIP is less cost effective
and more toxic compared to BEP. Conclusion: In view of the greater
toxicity and cost of therapy, as well as lack of either overall or
disease free survival advantage, VIP is not a preferred option for
patients with high-risk germ cell tumors in the Indian setting and it
is still advisable to treat patients with BEP
Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors
Background: In patients with small-volume disseminated disease of germ
cell tumors, cure can be achieved with four cycles of bleomycin,
etoposide, and cisplatin (BEP). However, around 20% of these cases are
not curable. Strategies to improve cure rates have shown that none of
the currently available modalities were superior to the others. Among
the most used ones, BEP and VIP (etoposide, cisplatin, and ifosfamide)
have been the most studied. However, there are no reports comparing the
two, except for a few in abstract forms from southern India. Therefore,
we did a treatment outcome and cost-effectiveness analysis of two
chemotherapeutic regimens (BEP vs VIP) that are used in poor-prognosis
metastatic germ cell tumors. Materials and Methods: All male patients
with germ cell tumors, diagnosed as having poor risk by IGCCCG, between
January 2002 and December 2004 were included in the study. Clinical,
laboratory, and other data were recorded. The patients were stratified
into two categories on the basis of the type of chemotherapeutic
regimen they received. Results: In all, 46 patients were analyzed, with
a median follow up of 26.6 months. The baseline characteristics (age,
stage, PS, histology, and serum markers) were not different in the two
treatment arms. There is no significant difference in the outcome with
either of the chemotherapeutic modalities. VIP is less cost effective
and more toxic compared to BEP. Conclusion: In view of the greater
toxicity and cost of therapy, as well as lack of either overall or
disease free survival advantage, VIP is not a preferred option for
patients with high-risk germ cell tumors in the Indian setting and it
is still advisable to treat patients with BEP
A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study
The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL